Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$231.33
pos +6.15
+2.73%
Today's Range: 226.00 - 234.20 | BIIB Avg Daily Volume: 1,384,900
Last Update: 05/21/13 - 4:00 PM EDT
Volume: 1,364,463
YTD Performance: 53.84%
Open: $226.17
Previous Close: $225.18
52 Week Range: $126.39 - $234.46
Oustanding Shares: 237,374,815
Market Cap: 53,452,060,842
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 9 9 9
Moderate Buy 1 1 1 1
Hold 9 11 11 11
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.90 2.10 2.10 2.10
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 01/18/01
Price Earnings Ratio: 35.74
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
35.74 35.70 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
36.66% 75.81% 357.22%
GROWTH 12 Mo 3 Yr CAGR
Revenue -13.30 0.26 0.08
Net Income 11.80 0.42 0.12
EPS 14.30 0.72 0.20
Earnings for BIIB:
EBITDA 1.38B
Revenue 4.38B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $1.78 $2.07 $7.88 $9.88
Number of Analysts 4 4 4 4
High Estimate $1.96 $2.13 $8.03 $10.71
Low Estimate $1.62 $1.98 $7.77 $9.09
Prior Year $1.82 $1.90 $6.53 $7.88
Growth Rate (Year over Year) -2.06% 8.82% 20.64% 25.45%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
fwpharma
fwpharma: ViewPoints: Biogen Idec looks to follow Tecfidera success with pegylated Avonex approval http://t.co/Z7PQOXfiEA $BIIB
43 minutes ago from bitly
cadetwarrior
cadetwarrior: If anyone locates the $biib interview about safer injection Technology please post $unis . Unilife soars in the near future
4 hours ago from Twitter for Android
wisefundmanager
wisefundmanager: $BIIB, $OPEN, $BABY, $LUX, $XTEX, $FENG, $COST, #Bullish, #BUY Signal, #stocks #investing
4 hours ago from InveSocial
JOHNDHasseyJr
JOHNDHasseyJr: RT @NASDAQ: NASDAQ-100 AHI at 3027.16 (up 0.02%) movers: $NTAP, $GILD, $EBAY, $INTU, $BIIB http://t.co/3xWOe5qVgh #nasdaq
5 hours ago from Twitter for iPhone
TARBIOTECH
TARBIOTECH: http://t.co/pPyypByn1f ADVANTAGE $BIIB
5 hours ago from web
AsherCJr
AsherCJr: Stocks Get A Boost From Dovish Fed Remarks http://t.co/AtgCrTJWeD #IBDEditorials via @IBDinvestors $ALK $BIIB $ARMH $MDCO $WWWW
7 hours ago from Tweet Button
DozenStocks
DozenStocks: Top Nasdaq100 #Stocks Performance $SHLD $NUAN $CHRW $BIIB $VRTX $ALXN $ATVI $WDC $AMGN $AVGO $FAST $BBBY more@ http://t.co/YdSIjG11yN
8 hours ago from CJ AutoTweeter
DozenStocks
DozenStocks: Top Nasdaq100 #Stocks Trend $ATVI $AVGO $XLNX $COST $CHKP $ORLY $KLAC $SHLD $BIIB $WDC $KRFT $ORCL $SPLS $AMZN @ http://t.co/YdSIjG11yN
8 hours ago from CJ AutoTweeter
DozenStocks
DozenStocks: Top S&P500 #Stocks Performance $MDT $MRK $AZO $TDC $CHRW $BIIB $CVC $ALXN $HD $ACT $KSS $WDC $NUE $AMGN more@ http://t.co/RPeaHBZz9y
8 hours ago from CJ AutoTweeter
StockPlayer6
StockPlayer6: RT @CAMAR024: Watchlist for Wed. 5/22/13 is up http://t.co/XKru2G8LiJ $LOTE $PLUG $TDEY $FNMA $FMCC $NORX $LULU $AMZN $BIIB $GILD
8 hours ago from web

Biotech Makes a Comeback

By

Jim Cramer

 | May 10, 2013 | 12:52 PM EDT

Just a natural change in leadership.

Big Pharma Has Lost Its Way

By

Jim Cramer

 | May 3, 2013 | 7:23 AM EDT

Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.

Early-Morning Market Look

By

Doug Kass

 | May 1, 2013 | 7:37 AM EDT
Let's take a peek and overnight and morning markets.

bearishBiogen Idec downgraded at Goldman

May 1, 2013 | 7:30 AM EDT

BIIB was downgraded from Buy to Neutral, Goldman Sachs said. $215 price target. Valuation call, as the stock is up 44% since December. 

Rules of the Game: Biotechs in Rally Mode

By

Kate Stalter

 | Apr 26, 2013 | 6:00 PM EDT

Here are two quality names in the sector to watch for a pullback.

National Lemming Day

By

Jim Cramer

 | Apr 24, 2013 | 1:16 PM EDT

It’s the only thing that explains today’s action.

The Biotech Revaluation Is On

By

Jim Cramer

 | Apr 17, 2013 | 6:20 AM EDT

These four names in particular have made some stunning moves.

Remember, Everything Gets Exaggerated at First

By

Jim Cramer

 | Apr 15, 2013 | 7:43 AM EDT

Keep that in mind as the market reacts to China this morning.

Health Care Stocks Still Promising

By

Kate Stalter

 | Apr 11, 2013 | 10:24 AM EDT

Plenty of leadership remains in the health care sector and there’s reason to see further potential.

Consider Playing Catch-Up Via Biotech

By

Jim Cramer

 | Apr 10, 2013 | 3:32 PM EDT

Deep-in-the-money call options on these five names could provide a healthy return.

Columnist Conversation / Market Updates

NetApp (NTAP): Storing Up Disappointment
By

Chris Laudani

 | May 21, 2013 | 5:33 PM EDT
Co misses on revenues. Revenue rose (if you can call it that) 0.8% to $1.7 bin. (I was looking for 1.7% y/y rev growth.)...

Making a late move on NTAP
By

Robert Lang

 | May 21, 2013 | 3:46 PM EDT
We added a call spread for NTAP here, not as pricey as the move implies, the chart not looking too bad. I like this for...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.